Basilea Pharmaceutica Ag Stock Price To Earnings To Growth
| BSLN Stock | CHF 40.90 0.05 0.12% |
Basilea Pharmaceutica AG fundamentals help investors to digest information that contributes to Basilea Pharmaceutica's financial success or failures. It also enables traders to predict the movement of Basilea Stock. The fundamental analysis module provides a way to measure Basilea Pharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Basilea Pharmaceutica stock.
Basilea |
Basilea Pharmaceutica AG Company Price To Earnings To Growth Analysis
Basilea Pharmaceutica's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Basilea Pharmaceutica AG has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all Switzerland stocks is 100.0% higher than that of the company.
Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
Basilea Fundamentals
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 670.47 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.05 % | |||
| Shares Owned By Institutions | 28.93 % | |||
| Price To Earning | 190.88 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 148.12 M | |||
| Gross Profit | 30.89 M | |||
| EBITDA | 2.11 M | |||
| Net Income | (6.83 M) | |||
| Cash Per Share | 13.81 X | |||
| Total Debt | 94.54 M | |||
| Current Ratio | 5.84 X | |||
| Book Value Per Share | (5.67) X | |||
| Cash Flow From Operations | (32.02 M) | |||
| Earnings Per Share | 0.23 X | |||
| Target Price | 72.33 | |||
| Number Of Employees | 177 | |||
| Beta | 0.88 | |||
| Market Capitalization | 591.36 M | |||
| Total Asset | 247.27 M | |||
| Z Score | 3.6 | |||
| Net Asset | 247.27 M |
About Basilea Pharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Basilea Pharmaceutica AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Basilea Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Basilea Pharmaceutica AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Basilea Stock Analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.